Andres VALDIVIESO LOPEZ

Prof. Andres VALDIVIESO LOPEZ

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Annals of Surgery
Verified
Journal Article
Closed access
RRRicardo Robles
Ricardo Robles
JFJoan Figueras
Joan Figueras
VTVictor S. Turrión
Victor S. Turrión
CMCarlos Margarit
Carlos Margarit
AMAngel Moya
Angel Moya
PPPascual Parrilla
Pascual Parrilla
To assess the real utility of orthotopic liver transplantation (OLT) in patients with cholangiocarcinoma, we need series with large numbers of cases and long follow-ups. The aim of this paper is to review the Spanish experience in OLT for hilar and peripheral cholangiocarcinoma and to try to identify the prognostic factors that could influence survival. Palliative treatment of nondisseminated irresectable cholangiocarcinoma carries a zero 5-year survival rate. The role of OLT in these patients is controversial, due to the fact that the survival rate is lower than with other indications for transplantation and due to the lack of organs. We retrospectively reviewed 59 patients undergoing OLT in Spain for cholangiocarcinoma (36 hilar and 23 peripheral) over a period of 13 years. We present the results and prognostic factors that influence survival. The actuarial survival rate for hilar cholangiocarcinoma at 1, 3, and 5 years was 82%, 53%, and 30%, and for peripheral cholangiocarcinoma 77%, 65%, and 42%. The main cause of death, with both types of cholangiocarcinoma, was tumor recurrence (present in 53% and 35% of patients, respectively). Poor prognosis factors were vascular invasion (P < 0.01) and IUAC classification stages III-IVA (P < 0.01) for hilar cholangiocarcinoma and perineural invasion (P < 0.05) and stages III-IVA (P < 0.05) for peripheral cholangiocarcinoma. OLT for nondisseminated irresectable cholangiocarcinoma has higher survival rates at 3 and 5 years than palliative treatments, especially with tumors in their initial stages, which means that more information is needed to help better select cholangiocarcinoma patients for transplantation.

24 November 2014 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
EPEugenia Pareja
Eugenia Pareja
MCMiriam Cortes
Miriam Cortes
DHDavid Hervás
David Hervás
JMJosé Mir
José Mir
ALAndres VALDIVIESO LOPEZ
Andres VALDIVIESO LOPEZ
ALAgustin Lahoz
Agustin Lahoz

1 November 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
JBJavier Briceño
Javier Briceño
MCManuel Cruz-Ramírez
Manuel Cruz-Ramírez
MPMario Prieto-Velasco
Mario Prieto-Velasco
MNMiguel Navasa
Miguel Navasa
JUJorge Ortiz de Urbina
Jorge Ortiz de Urbina
MMManuel de la Mata
Manuel de la Mata

1 March 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
ALAndres VALDIVIESO LOPEZ
Andres VALDIVIESO LOPEZ
JBJ. Bustamante
J. Bustamante
MGM. Gastaca
M. Gastaca
JUJ.G. Uriarte
J.G. Uriarte
AVA. Ventoso
A. Ventoso
JUJ. Ortiz de Urbina
J. Ortiz de Urbina

1 February 2002 in Transplantation Proceedings
Verified
Journal Article
Closed access
FGF.J Gainza
F.J Gainza
ALAndres VALDIVIESO LOPEZ
Andres VALDIVIESO LOPEZ
NQN Quintanilla
N Quintanilla
GEG Errazti
G Errazti
MGM Gastaca
M Gastaca
JOJ Ortiz-De-Urbina
J Ortiz-De-Urbina

1 November 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
MGM. Gastaca
M. Gastaca
ALAndres VALDIVIESO LOPEZ
Andres VALDIVIESO LOPEZ
JPJ. Pijoan
J. Pijoan
GEG. Errazti
G. Errazti
MHM. Hernandez
M. Hernandez
JUJ. Ortiz de Urbina
J. Ortiz de Urbina